Otsuka and Lundbeck, developers of the schizophrenia drug, Abilify Maintena, approached us with a communications brief for a public affairs programme which would make a difference to the lives of more than 26 million people worldwide living with schizophrenia.  H+K recognized the need to go beyond the more traditional route of patient education, and focused … Read more